Consort Medical

FDA Approval of Development Programme

Consort Medical plc (“Consort Medical”) (LSE: CSRT), is delighted to announce that its development programme INJ300 has been granted FDA approval.

Bespak’s INJ300 development programme is an autoinjector for Sumatriptan by Dr. Reddy’s Laboratories. This is the first Bespak autoinjector programme to receive regulatory approval, following the acquisition of The Medical House.

Preparations are underway for product launch which is expected in Q1 2014, ahead of our previous expectations.

Jonathan Glenn, Consort Medical’s Chief Executive commented: “This regulatory approval of our first autoinjector represents a major milestone for Consort Medical’s Injectables technology, and is a significant step in the execution of our diversification strategy.”

  • News
  • Case Studies
  • Pages
  • Blogs
  • Locations
  • Experts